Teraimmune, Inc
Key technical assets of TeraImmune 1) Expansion of human regulatory T cells in vitro 2) Receptors targeting pathological immune cells (T cell/ B cell/ antigen presenting cell) Grant awards 1) SBIR phase 1 (NHLBI, NIH) in April 2018 - grant for small businesses, scientifically verified 2) PACT program (NHLBI, NIH) in November 2018 - service grant supporting overall process development of the cell manufacturing: establishment of standard operating procedure (SOP), QA/QC and regulatory service
7-day free trial · no credit card
Verified contacts
2
available on Kipplo
LinkedIn employees
1
11 to 50 range
Open roles
—
no listings
Distinct roles
2
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 2 verified contacts at Teraimmune, Inc
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
2 contacts with verified email or phone · masked until revealed.
Showing 1 of 2 verified contacts
Top roles at Teraimmune, Inc
2 distinct titles indexed · top 2 shown.
- 1korea office president
- 1senior scientist
Sign up to unlock all 2 contacts at Teraimmune, Inc
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 2 verified contacts at Teraimmune, Inc
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.